| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8153689 | NABRIVA | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
Mar, 2028
(4 years from now) | |
| US8071643 | NABRIVA | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
Jan, 2029
(5 years from now) | |
| US9120727 | NABRIVA | Process for the preparation of pleuromutilins |
May, 2031
(7 years from now) | |
Xenleta is owned by Nabriva.
Xenleta contains Lefamulin Acetate.
Xenleta has a total of 3 drug patents out of which 0 drug patents have expired.
Xenleta was authorised for market use on 19 August, 2019.
Xenleta is available in solution;intravenous dosage forms.
Drug patent challenges can be filed against Xenleta from 2028-08-19.
The generics of Xenleta are possible to be released after 23 May, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 19, 2024 |
| Generating Antibiotic Incentives Now (GAIN) | Aug 19, 2029 |
Drugs and Companies using LEFAMULIN ACETATE ingredient
NCE-1 date: 2028-08-19
Market Authorisation Date: 19 August, 2019
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
XENLETA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic